Results 11 to 20 of about 3,909 (222)
Terlipressin Induced Severe Hyponatremia [PDF]
Prague Medical Report, 2016 Terlipressin is a vasopressin analogue used for its vasoconstrictor effect in the treatment of variceal bleeding. Despite its good safety profile compared to vasopressin, some adverse reactions may occur during its use – e.g. hyponatremia.
Martin Šíma +3 more
doaj +3 more sources
Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes. [PDF]
JGH OpenABSTRACT Background Treatments for hepatorenal syndrome with acute kidney injury (HRS‐AKI) that are not FDA‐approved have been widely used in the United States (US) with variable outcomes. This study describes the practice patterns, outcomes, and healthcare utilization around vasopressor use before terlipressin approval in 2022. Methods A retrospective
Sanyal AJ +12 more
europepmc +2 more sources
Future indications for terlipressin therapy [PDF]
Alimentary Pharmacology & Therapeutics, 2004 SummaryVasoconstrictor agents such as terlipressin (Glypressin®) have been shown to have beneficial effects in the treatment of hepatorenal syndrome (HRS), in terms of improving renal function and subsequent survival rates. Patients with HRS have also been shown to have improved survival after liver transplantation if they receive terlipressin ...
Didier Lebrec
openalex +4 more sources
Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome
AAPS Open, 2022 The objective of this population pharmacokinetics (PK) analysis was to characterize the PK of terlipressin and its active metabolite, lysine-vasopressin (L-VP), in patients with hepatorenal syndrome (HRS), following intravenous administration of ...
Xiaofeng Wang, Khurram Jamil
doaj +1 more source
Terlipressin-induced hyponatraemia [PDF]
Critical Care, 2014 Terlipressin is a vasopressin (V1 receptor) agonist that causes splanchnic constriction and is used in the management of variceal bleeding. This case report demonstrates the profound hyponatraemia, sufficient to cause a fall in conscious level, developing following terlipressin administration for variceal gastrointestinal bleeding.
J Kilic, P Anderson, R Gray
openaire +2 more sources
Terlipressin‐induced foot ischemia [PDF]
Clinical Case Reports, 2020 AbstractTerlipressin‐induced peripheral ischemia is a rare side effect of the drug, which should be timely identified and treated to prevent permanent necrosis.
Ines Dakhlia +4 more
openaire +3 more sources
Terlipressin: Hopes Fulfilled or Dashed? [PDF]
Clinical Journal of the American Society of Nephrology, 2022 One of the most dreaded complications of end stage liver disease is hepatorenal syndrome AKI (HRS-AKI; formally known as hepatorenal syndrome 1 [HRS-1]). HRS-AKI carries a high mortality, and treatment options are limited. Guidelines recommend terlipressin as the first-line treatment of HRS-AKI;
Erik R. Swenson +4 more
openaire +2 more sources
Egyptian Journal of Anaesthesia, 2023 Background and Aims Liver transplantation is associated with hemodynamic instability. Systemic and Splanchnic circulations interact closely. Portal hypertension is linked to vasodilatory molecules resulting in arterial vasodilatation.
Reham Mustafa Hashim +4 more
doaj +1 more source
Canadian Journal of Gastroenterology and Hepatology, 2020 Ascites, a common complication in cirrhosis, is prone to the development of acute kidney injury or hepatorenal syndrome and can be complicated by circulatory dysfunction after paracentesis.
Zhaohui Bai +6 more
doaj +1 more source
Scientific Reports, 2022 Terlipressin with albumin, the recommended treatment for hepatorenal syndrome-acute kidney injury (HRS-AKI), is associated with adverse events. Furthermore, the course of AKI in patients with acute-on-chronic liver failure (ACLF) is unknown.
Anand V. Kulkarni +8 more
doaj +1 more source